United States ex rel. Franklin v. Parke-Davis (2004)
Qui tam cases filed by whistleblowers don’t just result in financial recoveries — someitmes they reshape entire industries. United States ex rel. Franklin v. Parke-Davis (2004) is an example of such industry-shifting cases.
The whistleblower in that case was Dr. David Franklin, a former medical liaison at Parke-Davis, a subsidiary of Warner-Lambert (later acquired by Pfizer). Franklin alleged that the company promoted the epilepsy drug Neurontin for unapproved, “off-label” uses such as bipolar disorder, migraines, and attention deficit disorder. While doctors may legally prescribe drugs for off-label uses, pharmaceutical companies cannot legally promote drugs for such uses.
Franklin filed a whistleblower lawsuit under the False Claims Act, alleging that Parke-Davis’s promotion led to false claims submitted to Medicaid and other government health programs. The case ultimately resulted in a $430 million settlement in 2004, one of the largest at the time for off-label marketing.
What makes this case notable isn’t just the dollar figure — it set a precedent. The Franklin case helped open the door for broader scrutiny of off-label marketing practices across the pharmaceutical industry. The case also highlights the critical role whistleblowers play in uncovering practices that put profits ahead of patients.
At Barrett Johnston, we see Franklin’s courage as an example of why whistleblower protections matter. Cases like his remind us that individuals who step forward can change the trajectory of healthcare fraud enforcement nationwide.
The government alleged Parke-Davis orchestrated an extensive and clandestine scheme to unlawfully promote its epilepsy drug Neurontin for unapproved uses. While physicians may legally prescribe drugs off-label, federal law prohibits pharmaceutical companies from marketing them for such purposes. The specifics alleged were:
– The company targeted conditions including bipolar disorder, migraines, and attention deficit disorder, with internal documents revealing promotion for more than a dozen unapproved conditions
– Medical liaisons were allegedly instructed to make false statements about Neurontin’s effectiveness and to downplay risks
– The scheme allegedly caused false claims to be submitted to Medicaid and other government health programs, as reimbursements for certain off-label prescriptions were prohibited
Parke-Davis and its parent company Warner-Lambert agreed to a $430 million settlement in May 2004 to resolve the whistleblower lawsuit. At the time, this was one of the largest recoveries against a pharmaceutical company in U.S. history.
Dr. David Franklin was the whistleblower who filed the 1996 qui tam lawsuit that exposed Parke-Davis’s illegal off-label marketing of an anticonvulsant drug.
Working as a medical liaison for only five months, he witnessed a company-wide scheme to promote the drug for unapproved conditions. When he raised internal concerns, a supervisor warned him that his career could not be guaranteed.
Undeterred, Franklin filed suit on behalf of the government under the False Claims Act. His evidence of ghostwriting (a practice where a drug company pays an outside medical writer to draft a clinical study or journal article, but then recruits a well-known physician or academic to attach their name as the lead author), sham studies, and kickbacks to doctors became the foundation of the case, ultimately leading to a $430 million settlement.
Neurontin, the brand name for gabapentin, was the sole drug at the center of the Parke-Davis fraud case. While the FDA had approved Neurontin only for partial seizures and postherpetic neuralgia, the company promoted it for more than a dozen unapproved conditions.
This gap between the drug’s narrow legal uses and the company’s aggressive marketing strategy made it the focus of the whistleblower lawsuit.
The Franklin case fundamentally changed how pharmaceutical companies approach off-label promotion. It established that marketing drugs for unapproved uses could trigger False Claims Act liability when those prescriptions were submitted to federal programs. The case exposed deceptive practices like ghostwriting and sham studies, prompting widespread industry reforms.
As a result:
– Companies overhauled compliance programs and imposed stricter oversight of sales and marketing activities
– The settlement opened the door for broader scrutiny of off-label marketing, leading to a cascade of subsequent investigations and billions in additional penalties against other manufacturers
– The case demonstrated that whistleblowers could successfully challenge long-standing industry practices and force meaningful change
Dr. Franklin had to work quickly. Hired in the spring of 1996, he was fired just five months later, leaving a narrow window to gather evidence.
He preserved internal documents, including marketing plans and training materials that detailed the scheme and showed executive approval. He documented his own experiences and the instructions to deceive doctors about Neurontin’s effectiveness, including a medical director’s admission that the conduct was “brazenly criminal.”
He also gathered records of inducement schemes, such as paying doctors lavish speaking fees and flying them to resorts as “educational” trips to persuade them to prescribe off-label.
The Franklin case is a landmark because it proved that pharmaceutical off-label marketing could be pursued as False Claims Act fraud. The $430 million settlement sent a clear message to the entire industry that promoting drugs for unapproved uses carried severe financial consequences.
– The case established that whistleblowers could successfully challenge long-standing, widespread industry practices using the FCA as their legal vehicle
– It exposed deceptive tactics like ghostwriting and sham studies, prompting lasting compliance reforms across the pharmaceutical sector
– The case set a precedent for subsequent off-label marketing cases against other major manufacturers, leading to billions in additional recoveries
Latest News & Insights
